Group B Meningococcal Disease in New Zealand: Epidemiology and Prevention

Research Review Educational Series E-Learning Module

Begin

Group B Meningococcal Disease in New Zealand: Epidemiology and Prevention

This Research Review Educational Series E-Learning Module is intended for New Zealand GPs and covers the risk factors for, and incidence and burden of meningococcal disease in New Zealand.  It reviews available vaccines for meningococcal disease including an in-depth review of the 4CMenB vaccine.  It is based on the Research Review Educational Series Publication ‘Group B Meningococcal Disease in New Zealand: Epidemiology and Prevention’.

Before starting the module please read the Research Review Educational Series publication, accessed through the link below:

CLICK HERE
to access the quiz source material
Educational Series - Group B Meningococcal Disease in New Zealand: Epidemiology and Prevention

The PDF through the link above can be viewed on screen, saved and printed.

This Educational Series E-Learning Module covers:

  • An overview of meningococcal disease.
  • Risk factors for meningococcal disease.
  • The incidence of meningococcal disease.
  • The burden of meningococcal disease.
  • Epidemiology of group B meningococcal disease in New Zealand.
  • Prevention of group B meningococcal disease in New Zealand (4CMenB).

Learning outcomes

After completing this module you should have an improved understanding of:

  • Risk factors associated with meningococcal disease.
  • The incidence of meningococcal disease.
  • The burden of meningococcal disease.
  • The epidemiology of group B meningococcal disease in New Zealand.
  • Prevention of group B meningococcal disease in New Zealand (4CMenB).

Contributing experts

Expert commentary is provided by:

Dr Sharon Wong, a paediatrician at Waitemata DHB who was involved with the New Zealand serogroup B meningococcal vaccine initiative. 

Dr Stewart Reid, a semi-retired GP, also involved in the New Zealand serogroup B meningococcal vaccine initiative.

Module questions have been developed by Dr Chris Tofield, who works in primary care skin cancer treatment, is clinical advisor at Bay of Plenty District Health Board, and consultant to Research Review.

Accreditation

“Group B Meningococcal Disease in New Zealand: Epidemiology and Prevention" E-Learning Module has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.
Further info

"Group B Meningococcal Disease in New Zealand: Epidemiology and Prevention" E-Learning Module has been endorsed by The College of Nurses and has been approved for 1 hour professional development. Valid until 5 November 2022.
Further info

References

  1. Ministry of Health. 2018. Immunisation Handbook 2017 (2nd edn). Wellington: Ministry of Health. Available at: https://www.health.govt.nz/publication/immunisation-handbook-2017 [Accessed January 2019].
  2. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007 Jan;31(1):3-14.
  3. Thompson MJ, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006 Feb 4;367(9508): 397-403.
  4. Whittaker R, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017 Apr 11;35(16):2034-2041.
  5. Rosenstein NE, et al. Meningococcal disease. N Engl J Med. 2001 May 3;344(18):1378-88.
  6. The Immunisation Advisory Centre. Meningococcal disease. Available at: http://www.immune.org.nz/diseases/meningococcal-disease [Accessed January 2019].
  7. The Institute of Environmental Science and Research Ltd. Invasive Meningococcal Disease Report: 23 November 2018. Available at: https://surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2018/QuarterlyreportMen23_11_2018.pdf [Accessed January 2019].
  8. Medsafe. New Zealand Data Sheet. BEXSERO Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) 0.5 mL suspension for injection. Available at: http://www.medsafe.govt.nz/profs/Datasheet/b/bexseroinj.pdf [Accessed January 2019].
  9. Lennon D, et al. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009; 49: 597-605.
  10. O’Hallahan J, et al. The strategy to control New Zealand’s epidemic of group B meningococcal disease. Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S293-8.
  11. Martin D and Lopez L. The Epidemiology of Meningococcal Disease in New Zealand in 2007. Institute of Environmental Science and Research Ltd (ESR) Wellington, New Zealand.
  12. Baker MG, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000 Oct;19(10):983-90.
  13. Ministry of Health. Meningococcal disease: information for general practitioners and emergency departments. Available at: https://www.health.govt.nz/our-work/diseases-and-conditions/meningococcal/meningococcal-disease-information-general-practitioners-and-emergency-departments [Accessed January 2019].
  14. Lennon D, et al. An outbreak of meningococcal disease in Auckland, New Zealand. Pediatr Infect Dis J. 1989 Jan;8(1):11-5.
  15. Baker MG, et al. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health. 2001 Oct;37(5):S13-9.
  16. Sexton K, et al. The New Zealand Meningococcal Vaccine Strategy: A tailor-made vaccine to combat a devastating epidemic. N Z Med J 2004; 117(1200):U1015.
  17. Arnold R, et al. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011 Sep 16;29(40):7100-6.
  18. Kelly C, et al. A prospective study of the effectiveness of the New Zealand Meningococcal B vaccine. Am J Epidemiol. 2007 Oct 1;166(7):817-23.
  19. Mills C, et al. Unanswered questions, the epidemiology of a community outbreak: meningococcal disease in Northland New Zealand, 2011. N Z Med J. 2013 Apr 19;126(1373):40-5.
  20. The Institute of Environmental Science and Research Ltd. Invasive Meningococcal Disease Report: 23 January 2019. Available at: https://surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2019/MeningococcalDisease_wk2-32019.pdf [Accessed January 2019].
  21. The Institute of Environmental Science and Research Ltd. Notifiable Diseases in New Zealand: Annual Report 2016. Porirua, New Zealand. Available at: https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2016/2016AnnualNDReportFinal.pdf [Accessed January 2019].
  22. Ministry of Health. Northland meningococcal vaccination programme: questions and answers. Available at: https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/meningococcal-disease-including-meningitis/northland-meningococcal-vaccination-programme-questions-and-answers [Accessed January 2019].
  23. Black S, et al. Toward a meningitis-free world. Sci Transl Med. 2012 Feb 29;4(123):123ps5. doi: 10.1126/scitranslmed.3003859.
  24. Strifler L, et al. The Health Burden of Invasive Meningococcal Disease: A Systematic Review. J Pediatric Infect Dis Soc. 2016 Dec;5(4):417-430.
  25. Pickering L, et al. Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis. Eur J Pediatr. 2018 Jun 20. doi: 10.1007/s00431-018-3192-0. [Epub ahead of print].
  26. Wang B, et al. Costs of Invasive Meningococcal Disease: A Global Systematic Review. Pharmacoeconomics. 2018 Oct;36(10):1201- 1222.
  27. Medsafe. New Zealand Data Sheet. Menactra®. Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine. Available at: http://www.medsafe.govt.nz/profs/Datasheet/m/menactrainj.pdf [Accessed January 2019].
  28. Medsafe. New Zealand Data Sheet. NIMENRIX™ injection with diluent. Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine. Available at: http://www.medsafe.govt.nz/profs/Datasheet/n/nimenrixinj.pdf [Accessed January 2019].
  29. Medsafe. New Zealand Data Sheet. NEISVAC-C®. Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate). Available at: http://www.medsafe.govt.nz/profs/datasheet/n/NeisVacCinj.pdf [Accessed January 2019].
  30. European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. Stockholm: ECDC; 2017. Available at: https://ecdc.europa.eu/en/publications-data/expert-opinion-introduction-meningococcal-b-4cmenb-vaccine-eueea [Accessed January 2019].
  31. Government of South Australia. SA Health. Meningococcal B Immunisation Program. Available at: https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+
    internet/health+topics/health+conditions+prevention+and+treatment
    /immunisation/immunisation+programs/meningococcal+b+immunisation+program     [Accessed January 2019].
  32. O’Ryan M, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014 Jan;74(1):15-30.
  33. Gossger N, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012 Feb 8;307(6):573-82.
  34. Vesikari T, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013 Mar 9;381(9869):825-35.
  35. Iro MA, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2017 Jan 5;35(2):395-402.
  36. Macias Parra M, et al. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase3b, randomized controlled trial. Vaccine. 2018 Nov 29;36(50):7609-7617.
  37. Findlow J, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015 Jun 26;33(29):3322-30.
  38. Nolan T, et al. Poster 1060 presented at: IDWeek, 4–8 October 2017; San Diego, CA, USA. Available at: https://idsa.confex.com/idsa/2017/webprogram/Paper66058.html [Accessed January 2019].
  39. Santolaya ME, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013 Nov;9(11):2304-10.
  40. Nolan T, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019 Jan 25. pii: S0264-410X(19)30028-3. doi: 10.1016/j.vaccine.2018.12.059. [Epub ahead of print].
  41. Martinón-Torres F, et al. Meningococcal B Vaccine Immunogenicity in Children with Defects in Complement and Splenic Function. Pediatrics. Pediatrics. 2018 Sep;142(3). pii: e20174250.
  42. Prymula R, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993-2004.
  43. Mentzer D, et al. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveill. 2018 Apr;23(17). doi: 10.2807/1560-7917.ES.2018.23.17.17-00468.
  44. De Wals P, et al. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada. Clin Infect Dis. 2017 May 1;64(9):1263-1267.
  45. De Serres G, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018 Dec 18;36(52):8039-8046.
  46. Duffy J, et al. Safety of a meningococcal group B vaccine used in response to two university outbreaks. J Am Coll Health. 2017 Aug-Sep;65(6):380-388.
  47. Bryan P, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018 Jun;2(6):395-403.
  48. Parikh SR, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016 Dec 3;388(10061):2775-2782.
  49. McNamara LA, et al. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak. Pediatrics. 2015 May;135(5):798-804.
  50. The Immunisation Advisory Centre. Paracetamol use with Bexsero(R) in children aged under 2 years. Available at: http://www.immune.org.nz/sites/default/files/resources/Written%20Resources/AdministrationParacetamolBexsero20180912V01Final.pdf [Accessed February 2019].
  51. Australian Technical Advisory Group on Immunisation. Advice for immunisation providers regarding the use of Bexsero(R) - a recombinant multicomponent meningococcal B vaccine (4CMenB). Available at: https://beta.health.gov.au/resources/publications/atagi-advice-on-the-use-of-bexseror-vaccine [Accessed February 2019].
  52. Public Health England. Using paracetamol to prevent and treat fever after MenB vaccination. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/717281/PHE_paracetamol-menB-A4-2018_01.pdf [Accessed February 2019].
‹Previous Next›